• Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

9EY:GR

4.826 EUR 0.142 2.86%

As of 03:54:12 ET on 08/21/2014.

Snapshot for Endocyte Inc (9EY)

Open: 4.834 Day's Range: 4.796 - 4.834 Volume: 150
Previous Close: 4.968 52wk Range: 4.350 - 29.050 1-Yr Rtn: -58.66%

Stock Chart for 9EY

No chart data available.
  • 9EY:GR 4.826
  • 1D
  • 1M
  • 1Y
4.968
Interactive 9EY Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 9EY

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.0470
Est. PEG Ratio -
Market Cap (M EUR) 200.52
Shares Outstanding (M) 41.55
30 Day Average Volume 625
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/05/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 9EY

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for 9EY

Endocyte Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The Company uses a proprietary technology to create small molecule drug conjugates, or SMDCs, and companion imaging diagnostics that actively target receptors that are over-expressed on diseased cells, relative to healthy cells.

P Ron EllisPresident/CEO/Co-FounderMichael A ShermanCFO/COO
Philip S LowChief Science OfficerDavid D MeekChief Commercial Officer
More Company Profile & Key Executives for 9EY

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil